Handelsavisen
prelaunch
Companies Healthcare 4198.TWO
41
4198.TWO TPEx Advanced Medical Equipment & Technology

4198.Two

$37,15
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
-22,8 %
ROE
-20,9 %
Net margin
-23,2 %
Debt / equity
0,13
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

4198.TWO operates in the Advanced Medical Equipment & Technology industry, specializing in the development and provision of medical equipment and technology solutions.

Business. 4198.TWO operates in the Advanced Medical Equipment & Technology industry, specializing in the development and provision of medical equipment and technology solutions.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-20,9 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 4198.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 4198.TWO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    4198.TWO operates in the Advanced Medical Equipment & Technology industry, specializing in the development and provision of medical equipment and technology solutions.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryAdvanced Medical Equipment & Technology
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a low debt-to-equity ratio of 0.13, indicating a conservative approach to leverage. With cash and equivalents amounting to 106,846,000 TWD, the company maintains a strong liquidity position, as reflected in a current ratio of 2.93. However, the company reported negative operating and net income, with operating income at -46,569,000 TWD and net income at -47,295,000 TWD, suggesting a lack of profitability. The return on equity and return on assets are also negative, at -20.88% and -12.54%, respectively, indicating poor returns on invested capital.

    The company's profitability is below the industry median, as evidenced by the negative operating and net income figures. The negative returns on equity and assets further underscore the company's underperformance in generating returns for shareholders and utilizing assets efficiently. The company's operating cash flow is also negative at -26,657,000 TWD, which may indicate challenges in generating sufficient cash from operations to sustain its activities.

    The company's revenue is concentrated in a single segment, as no segmental breakdown is provided in the available data. The geographic exposure is not specified, but the company's operations are likely centered in the region where it is listed. The lack of segmental and geographic diversification may pose a concentration risk, as the company's performance is tied to a single market or product line.

    The company's growth trajectory is uncertain, as the most recent revenue figure is 204,212,000 TWD, and there is no indication of a clear growth path in the near term. The negative operating and net income figures suggest that the company may need to address its cost structure or revenue generation strategies to achieve profitability. The company's capital expenditure of -3,522,000 TWD indicates a reduction in investment in long-term assets, which may affect its ability to grow and innovate.

    The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's free cash flow is negative at -31,913,000 TWD, which may limit its ability to fund operations and investments without external financing. The dilution potential is low, as the number of shares outstanding for both basic and diluted shares is the same, indicating no imminent threat of share dilution.

    Recent events related to the company include the latest actual revenue of 463,700,000 TWD, as reported by analyst estimates. This figure is significantly higher than the most recent reported revenue, suggesting a potential discrepancy or a need for further investigation into the company's financial reporting.

    Key takeaways
    • The company has a strong liquidity position with a current ratio of 2.93 and significant cash and equivalents.
    • The company is not profitable, with negative operating and net income figures.
    • The company's return on equity and return on assets are negative, indicating poor returns on invested capital.
    • The company's growth trajectory is uncertain, with no clear path to profitability.
    • The company's risk profile is low in terms of liquidity and dilution, but its financial performance is a concern.
    • "margin_outlook_rationale": "The company's margin outlook is negative due to the reported negative operating and net income figures.",

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $37,15
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $226.5M
    Net cash
    $78.4M
    Current ratio
    2.9
    Debt / equity
    0.1
    ROA
    -12.5%
    ROE
    -20.9%
    Cash conversion
    56.0%
    CapEx / revenue
    -1.7%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-22,8 %Below median
    Net Margin-23,2 %Below median
    ROE-20,9 %Below median
    Capex / Rev-1,7 %Above median
    D/E0,13Below median
    Cash Conv0,56Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • 4198.TWO Market data — financials · 2026-05-26
    • S&S Healthcare Holding Ltd Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    4198.TWOCanonical
    TPEx · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage